Premium
Clinical efficacy of reversible and selective inhibitors of monoamine oxidase A in major depression
Author(s) -
Paykel E. S.
Publication year - 1995
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1995.tb05920.x
Subject(s) - moclobemide , monoamine oxidase , melancholia , tricyclic , monoamine oxidase a , placebo , depression (economics) , monoamine neurotransmitter , pharmacology , medicine , monoamine oxidase inhibitor , psychiatry , clinical efficacy , psychology , serotonin , antidepressant , chemistry , mood , enzyme , biochemistry , anxiety , alternative medicine , receptor , macroeconomics , pathology , economics
This article reviews efficacy studies of the reversible selective inhibitor of monoamine oxidase A (MAO‐A) nioclobemide, which has now received extensive evaluation. Placebo‐controlled trials have shown it clearly to be effective. In comparisons with tricyclic and similar antidepressants and with serotonin reuptake inhibitors, it has been found of equal efficacy to these standard drugs. Because of previous suggestions that older MAO inhibitors are particularly effective in depressions characterized as alypical, the effects in subtypes are of particular interest. The evidence indicates that moclobemide is effective in typical severe depression with melancholia rather than being limited to less lypical subtypes.